KyungdongPharm KRX:011040KOSDAQ
경동제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked9since Sep 11
In Q2 2026, KyungdongPharm reported revenue of ₩52.3bn, up 5.8% year on year, and operating profit of ₩3.7bn. KyungdongPharm (경동제약) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Insider buying Screener
KyungdongPharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩52.3bn | +5.8% | ₩3.7bn margin 7.1% | ₩5.8bn |
| Q1 2026 | ₩47.8bn | +4.4% | ₩2.4bn margin 5.0% | ₩4.7bn |
| Q4 2025 derived | ₩52.2bn | +5.3% | ₩2.6bn margin 4.9% | ₩2.8bn |
| Q3 2025 | ₩48.9bn | -1.5% | ₩3.1bn margin 6.3% | ₩4.4bn |
| Q2 2025 | ₩49.4bn | -0.6% | ₩478m margin 1.0% | −₩423m |
| Q1 2025 | ₩45.8bn | +1.6% | ₩1.5bn margin 3.3% | ₩1.6bn |
| Q4 2024 derived | ₩49.5bn | +10.6% | ₩2.2bn margin 4.5% | ₩2.6bn |
| Q3 2024 | ₩49.6bn | +27.1% | ₩529m margin 1.1% | ₩53m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
KyungdongPharm top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.